Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04262869 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Oct 27, 2021 | clinicaltrials |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab | withdrawn | Early Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 0 | Oct 8, 2021 | clinicaltrials |
| NCT04160559 |
| Green Tea Combined With Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer |
| withdrawn |
| N/A |
| 0 |
| Xinqiao Hospital of ChongqingOTHER |
| 1 |
| Sep 8, 2021 |
| clinicaltrials |
| NCT03431415 | Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer(RAXSIA) | withdrawn | N/A | 0 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | withdrawn | Phase 1 / Phase 2 | 0 | NextCure, Inc.INDUSTRY | 0 | Aug 18, 2021 | clinicaltrials |
| NCT04085081 | Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT03245177 | Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)(PARIS) | withdrawn | Phase 1 | 0 | Prof Corinne Faivre-FinnOTHER | 0 | Jul 28, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT00380666 | The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer | withdrawn | N/A | 0 | University of AarhusOTHER | 0 | May 6, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04069442 | cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors(LUNG-PREDICT) | withdrawn | — | 0 | University Hospital, GrenobleOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT01237171 | A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer | withdrawn | — | 0 | IsoRay Medical, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | withdrawn | Phase 2 | 0 | Ochsner Health SystemOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 3, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 20, 2020 | clinicaltrials |
| NCT04201145 | Pembrolizumab + Defactinib In Pleural Mesothelioma | withdrawn | Phase 1 | 0 | Raphael Bueno, MDOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | withdrawn | Phase 2 | 0 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Stephanie SmiddyOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03501056 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03421678 | Ethnic/Racial Differences in Metabolism and DNA Adduct Formation | withdrawn | — | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Oct 5, 2020 | clinicaltrials |
| NCT03409341 | Personalizing Immune Checkpoint Inhibitor Therapy | withdrawn | — | 0 | Holy Cross Hospital, MarylandOTHER | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02451865 | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT03713099 | NEUWAVE Flexible Probe Study #2 | withdrawn | N/A | 0 | Ethicon, Inc.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03574220 | Pembrolizumab After Lung SBRT for Medically Inoperable Early Stage Non-small Cell Lung Cancer | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Apr 7, 2020 | clinicaltrials |
| NCT03674450 | Lung Heart Rate Variability(HRV) | withdrawn | N/A | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT01383668 | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 0 | Apr 1, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT00818714 | Stereotactic Body Radiation Therapy (SBRT) as a Boost After Definitive Concurrent Chemoradiation (ChemoRT) for Non-Small Cell Lung Cancer (NSCLC) GCC 0516 | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 0 | Mar 18, 2020 | clinicaltrials |
| NCT03302221 | Regional Haemodynamic Changes in Radial Artery Assessment With Continuous Pulsed-wave Doppler Ultrasound | withdrawn | Phase 4 | 0 | China Medical University, ChinaOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03678090 | The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion. | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT03498222 | Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin(iTRAP) | withdrawn | Phase 1 | 0 | Queen Mary University of LondonOTHER | 0 | Feb 25, 2020 | clinicaltrials |
| NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | withdrawn | Phase 1 | 0 | Acrotech Biopharma Inc.INDUSTRY | 0 | Jan 23, 2020 | clinicaltrials |
| NCT03110939 | Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer | withdrawn | N/A | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03872440 | PDX Models From EGFR Mutant Tumors | withdrawn | — | 0 | Addario Lung Cancer Medical InstituteOTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03529084 | Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Nov 22, 2019 | clinicaltrials |
| NCT01993901 | The Influence of CSRT-led Telephone Follow-up on ESAS Scores in Patients Who Have Been Treated With Lung SBRT | withdrawn | N/A | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 19, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Oct 27, 2021source: clinicaltrials